The Horizon programme contains a variety of mRNA assets in varying stages of development, including a preclinical in vivo ...
The MarketWatch News Department was not involved in the creation of this content. Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 17, 2026 /PRNewswire/ -- Equity-Insider.com News ...
The world of biologics is moving far beyond traditional monoclonal antibodies, and companies across the biopharmaceutical landscape are racing to keep pace. From multispecific antibodies to ...
Endogenous RNA is central to protein control and, ultimately, cellular function. Synthetic RNA is an important tool for biological research and is also offering a new generation of promising ...
Join host Neil Lander on Chromatography Life as he interviews, Arnaud Delobel, R&D and Innovation Director at Quality Assistance. They discuss the challenges of chromatographic analysis for new ...
Biogen isn’t shy about aspirations to expand beyond neurology and further establish itself in immunology and rare diseases. Recent business development deals have focused on enhancing the company’s ...
Biomedical image analysis is critical to biomedical discovery because imaging is one of the most important tools for studying physiology, anatomy and function at multiple scales from the organelle ...
Provides broad overview of Company's research and early development programs expected to continue to fuel future ...
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 17, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – More than 2,100 oncology clinical trials were initiated globally in 2024, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results